Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT4R) Agonist Activities As Potential Agents against Alzheimer’s Disease: The Design of Donecopride

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT

Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 315,771 · see citing works

A short history of SHELX

Sheldrick, G. M. (2007) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767307043930 · Cited by 87,861 · see citing works

A new and rapid colorimetric determination of acetylcholinesterase activity

Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,221 · see citing works

Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen

Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763 · see citing works

Can the pharmaceutical industry reduce attrition rates?

Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · see citing works

High-Resolution Crystal Structure of an Engineered Human β 2 -Adrenergic G Protein–Coupled Receptor

Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G. F., Thian, F. S., Kobilka, T. S., Choi, H., Kühn, P., Weis, W. I., Kobilka, B. K., et al. (2007) · Science · doi:10.1126/science.1150577 · Cited by 3,280 · see citing works

Very fast empirical prediction and rationalization of protein pK a values

Li, H., Robertson, A. D., & Jensen, J. H. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20660 · Cited by 2,058 · see citing works

Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation

Jones, G., Willett, P., & Glen, R. C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(95)80037-9 · Cited by 1,548 · see citing works

An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”

Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455 · see citing works

Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands

Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J. D., Franklin, M. C., & Height, J. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300871x · Cited by 1,377 · see citing works

Designed Multiple Ligands. An Emerging Drug Discovery Paradigm

Morphy, R., & Ranković, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,237 · see citing works

Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152 · see citing works

Alzheimer's disease: strategies for disease modification

Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,060 · see citing works

Hybrid Molecules with a Dual Mode of Action: Dream or Reality?

Meunier, B. (2007) · Accounts of Chemical Research · doi:10.1021/ar7000843 · Cited by 942 · see citing works

From magic bullets to designed multiple ligands

Morphy, R., Kay, C., & Ranković, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 731 · see citing works

World Alzheimer Report 2010: The global economic impact of dementia

Wimo, A. B., & Prince, M. J. (2010) · Cited by 559 · see citing works

beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies.

Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 523 · see citing works

Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

Leon, R. M., Garcı́a, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 442 · see citing works

Development of a radioligand binding assay for 5‐HT4 receptors in guinea‐pig and rat brain

Grossman, C. J., Kilpatrick, G. J., & Bunce, K. T. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13617.x · Cited by 290 · see citing works

Lipoic acid as a novel treatment for Alzheimer's disease and related dementias

Holmquist, L., Stuchbury, G., Berbaum, K., Muscat, S., Young, S. A., Häger, K., Engel, J., & Münch, G. W. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.07.001 · Cited by 286 · see citing works

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Liu, L., & Duff, K. (2008) · Journal of Visualized Experiments · doi:10.3791/960 · Cited by 268 · see citing works

3-(4-{[Benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation: A Dual Function Lead for Alzheimer's Disease Therapy

Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., & Recanatini, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0340602 · Cited by 268 · see citing works

Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges

Morphy, R., & Ranković, Z. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315594 · Cited by 262 · see citing works

Multi-Target-Directed Drug Design Strategy: From a Dual Binding Site Acetylcholinesterase Inhibitor to a Trifunctional Compound against Alzheimer’s Disease

Bolognesi, M. L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., & Melchiorre, C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701225u · Cited by 262 · see citing works

Alzheimer disease: progress or profit?

Mount, C., & Downton, C. (2006) · Nature Medicine · doi:10.1038/nm0706-780 · Cited by 262 · see citing works

Multi-Target Drugs: The Trend of Drug Research and Development

Lu, J., Pan, W., Yuanjia, H., & Wang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040262 · Cited by 259 · see citing works

Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease

STERLING, J. J., Herzig, Y., Goren, T., Finkelstein, N., Lerner, D., Goldenberg, W., MISKOLCZI, I., Molnar, S., Rantal, F., Tamás, T., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020120c · Cited by 249 · see citing works

The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics

Carreiras, M. C., Mendes, E., Perry, M. D. J., Francisco, A., & Marco‐Contelles, J. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990135 · Cited by 242 · see citing works

Multi-Target-Directed Ligands in Alzheimer's Disease Treatment

Bajda, M., Guzior, N., Ignasik, M., & Malawska, B. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797535245 · Cited by 240 · see citing works

Tacrine Derivatives and Alzheimers Disease

Tumiatti, V., Minarini, A., Bolognesi, M. L., Milelli, A., Rosini, M., & Melchiorre, C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791111206 · Cited by 225 · see citing works

Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors: New Disease-Modifying Agents for Alzheimer's Disease

Muñoz-Ruiz, P., Rubio, L., García‐Palomero, E., Dorronsoro, I., del Monte-Millán, M., Valenzuela, R., Usán, P., de Austria, C., Bartolini, M., Andrisano, V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503289 · Cited by 221 · see citing works

Therapies for Alzheimer's disease

Melnikova, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2314 · Cited by 219 · see citing works

5-HT4 Receptors

Bockaert, J., Claeysen, S., Compan, V., & Dumuis, A. (2004) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007043482615 · Cited by 207 · see citing works

Fragments, network biology and designing multiple ligands

Morphy, R., & Ranković, Z. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.006 · Cited by 204 · see citing works

Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease

Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202 · see citing works

The Physicochemical Challenges of Designing Multiple Ligands

Morphy, R., & Ranković, Z. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603015 · Cited by 194 · see citing works

Inhibition of Acetylcholinesterase, β-Amyloid Aggregation, and NMDA Receptors in Alzheimer’s Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush

Rosini, M., Simoni, E., Bartolini, M., Cavalli, A., Ceccarini, L., Pascu, N., McClymont, D. W., Tarozzi, A., Bolognesi, M. L., Minarini, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800577j · Cited by 186 · see citing works

Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence

Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182 · see citing works

A Small Molecule Targeting the Multifactorial Nature of Alzheimer's Disease

Cavalli, A., Bolognesi, M. L., Capsoni, S., Andrisano, V., Bartolini, M., Margotti, E., Cattaneo, A., Recanatini, M., & Melchiorre, C. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700256 · Cited by 180 · see citing works

How to design multi-target drugs

Korcsmaros, T. D., Szalay, M., Böde, C., Kovács, I. A., & Csermely, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.6.799 · Cited by 162 · see citing works

Propargylamine-derived multitarget-directed ligands: fighting Alzheimer’s disease with monoamine oxidase inhibitors

Bolea, I., Gella, A., & Unzeta, M. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0948-y · Cited by 158 · see citing works

The benefits of the multi-target approach in drug design and discovery

Espinoza-Fonseca, M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.09.011 · Cited by 142 · see citing works

One‐compound‐multiple‐targets strategy to combat Alzheimer's disease

Zhang, H. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.09.006 · Cited by 139 · see citing works

Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment

Lecoutey, C., Hédou, D., Fréret, T., Giannoni, P., Gaven, F., Since, M., Bouët, V., Ballandonne, C., Corvaisier, S., Malzert‐Fréon, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410315111 · Cited by 136 · see citing works

Propidium-Based Polyamine Ligands as Potent Inhibitors of Acetylcholinesterase and Acetylcholinesterase-Induced Amyloid-β Aggregation

Bolognesi, M. L., Andrisano, V., Bartolini, M., Banzi, R., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049156q · Cited by 136 · see citing works

Novel Class of Quinone-Bearing Polyamines as Multi-Target-Directed Ligands To Combat Alzheimer's Disease

Bolognesi, M. L., Banzi, R., Bartolini, M., Cavalli, A., Tarozzi, A., Andrisano, V., Minarini, A., Rosini, M., Tumiatti, V., Bergamini, C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070559a · Cited by 134 · see citing works

Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease

Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 117 · see citing works

Novel Multipotent Tacrine−Dihydropyridine Hybrids with Improved Acetylcholinesterase Inhibitory and Neuroprotective Activities as Potential Drugs for the Treatment of Alzheimer's Disease

Marco, J. L., Leon, R. M., Rı́os, C. D. L., Guglietta, A., Terencio, J. V., López, M. G., Garcı́a, A. G., & Villarroya, M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061047j · Cited by 116 · see citing works

Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer’s disease

Giannoni, P., Gaven, F., Bundel, D. D., Baranger, K., Marchetti, E., Roman, F. S., Valjent, E., Marin, P., Bockaert, J., Rivera, S., et al. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00096 · Cited by 108 · see citing works

Pharmacological characterization of two novel and potent 5‐HT₄receptor agonists, RS 67333 and RS 67506,<i>in vitro</i>and<i>in vivo</i>

Eglen, R. M., Bonhaus, D. W., Johnson, L. G., Leung, E., & Clark, R. D. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb16628.x · Cited by 102 · see citing works

Synthesis and Structure–Affinity Relationships of Selective High-Affinity 5-HT 4 Receptor Antagonists: Application to the Design of New Potential Single Photon Emission Computed Tomography Tracers

Dubost⧫, E., Dumas, N., Fossey, C., Magnelli, R., Butt‐Gueulle, S., Ballandonne, C., Caignard, D. H., Dulin, F., Santos, J. S. O., Millet, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300943r · Cited by 101 · see citing works

Designing Multi-Target Drugs

(2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912 · Cited by 96 · see citing works

Multi-target Design Strategies in the Context of Alzheimer’s Disease: Acetylcholinesterase Inhibition and NMDA Receptor Antagonism as the Driving Forces

Rosini, M., Simoni, E., Minarini, A., & Melchiorre, C. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1250-1 · Cited by 94 · see citing works

New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol

Mao, F., Yan, J., Li, J., Jia, X., Miao, H., Sun, Y., Huang, L., & Li, X. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00998c · Cited by 91 · see citing works

Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases

Pisani, L., Catto, M., Leonetti, F., Nicolotti, O., Stefanachi, A., Campagna, F., & Carotti, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797379302 · Cited by 90 · see citing works

Cystamine-tacrine dimer: A new multi-target-directed ligand as potential therapeutic agent for Alzheimer’s disease treatment

Minarini, A., Milelli, A., Tumiatti, V., Rosini, M., Simoni, E., Bolognesi, M. L., Andrisano, V., Bartolini, M., Motori, E., Angeloni, C., et al. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.007 · Cited by 85 · see citing works

The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30

Youdim, M. B. H. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025288 · Cited by 84 · see citing works

Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone for Potential Use against Alzheimer's Disease

Melchiorre, C., Andrisano, V., Bolognesi, M. L., Budriesi, R., Cavalli, A., Cavrini, V., Rosini, M., Tumiatti, V., & Recanatini, M. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810452 · Cited by 81 · see citing works

MTDL Design Strategy in the Context of Alzheimers Disease: From Lipocrine to Memoquin and Beyond

Bolognesi, M. L., Rosini, M., Andrisano, V., Bartolini, M., Minarini, A., Tumiatti, V., & Melchiorre, C. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315585 · Cited by 79 · see citing works

Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases

Prati, F., Uliassi, E., & Bolognesi, M. L. (2014) · MedChemComm · doi:10.1039/c4md00069b · Cited by 77 · see citing works

Searching for the Multi-Target-Directed Ligands against Alzheimer’s disease: Discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities

Huang, W., Tang, L., Shi, Y., Huang, S., Xu, L., Sheng, R., Wu, P., Li, J. X., Zhou, N., & Hu, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.061 · Cited by 75 · see citing works

Enhanced neuronal plasticity and elevated endogenous sAPPα levels in mice over‐expressing MMP9

Fragkouli, A., Papatheodoropoulos, C., Georgopoulos, S., Stamatakis, A., Stylianopoulou, F., Tsilibary, E. C., & Tzinia, A. K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07637.x · Cited by 64 · see citing works

Effects of purine analogues on spontaneous alternation in mice

Hooper, N. K., Fraser, C. M., & Stone, T. W. (1996) · Psychopharmacology · doi:10.1007/bf02246579 · Cited by 64 · see citing works

From Dual Binding Site Acetylcholinesterase Inhibitors to Multi-Target-Directed Ligands (MTDLs): A Step Forward in the Treatment of Alzheimers Disease

Bolognesi, M. L., Minarini, A., Rosini, M., et al. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708785740652 · Cited by 64 · see citing works

Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders

Geldenhuys, W. J., & der Schyf, C. J. V. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.744746 · Cited by 59 · see citing works

Polyamines in Drug Discovery: From the Universal Template Approach to the Multitarget-Directed Ligand Design Strategy

Melchiorre, C., Bolognesi, M. L., Minarini, A., Rosini, M., & Tumiatti, V. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100293f · Cited by 57 · see citing works

Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT4 receptor activation (RS67333) on object recognition in mice

Fréret, T., Bouët, V., Quiedeville, A., Née, G., Dallemagne, P., Rochais, C., & Boulouard, M. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.02.012 · Cited by 55 · see citing works

The Deacylation Step of Acetylcholinesterase: Computer Simulation Studies

Vagedes, P., Rabenstein, B., Åqvist, J., Marelius, J., & Knapp, E. (2000) · Journal of the American Chemical Society · doi:10.1021/ja0004581 · Cited by 55 · see citing works

A steric blockade model for inhibition of acetylcholinesterase by peripheral site ligands and substrate

Rosenberry, T. L., Mallender, W. D., Thomas, P. J., et al. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00017-4 · Cited by 55 · see citing works

Chronic 5-HT4 receptor activation decreases Aβ production and deposition in hAPP/PS1 mice.

Tesseur, I., Pimenova, A. A., Lo, A. C., Ciesielska, M., Lichtenthaler, S., Maeyer, J. D. D., Schuurkes, J., D'Hooge, R., & de Strooper, B. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.01.020 · Cited by 53 · see citing works

Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer’s disease therapy

Li, Y., Peng, P., Tang, L., Hu, Y., Hu, Y., & Sheng, R. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.009 · Cited by 52 · see citing works

Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil

Youdim, M. B. H., Amit, T., Bar‐Am, O., Weinreb, O., & Yogev-Falach, M. (2006) · Neurotoxicity Research · doi:10.1007/bf03033355 · Cited by 46 · see citing works

Identification of Multiple 5-HT4Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease

Brodney, M. A., Johnson, D. E., Sawant‐Basak, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300953p · Cited by 46 · see citing works

Lipoic Acid, a Lead Structure for Multi-Target-Directed Drugs for Neurodegeneration

Bolognesi, M. L., Minarini, A., Tumiatti, V., & Melchiorre, C. (2006) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955706778742731 · Cited by 44 · see citing works

In vitroandin vivopharmacological profile of UFP‐512, a novel selective δ‐opioid receptor agonist; correlations between desensitization and tolerance

Aguila, B., Coulbault, L., Boulouard, M., Lιveillι, F., Davis, A., Tσth, G., Borsodi, A. D., Balboni, G., Salvadori, S., Jauzac, P., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707497 · Cited by 39 · see citing works

Chemical and Pharmacological Studies on Enantiomerically Pure p‐Methoxytacripyrines, Promising Multi‐Target‐Directed Ligands for the Treatment of Alzheimer’s Disease

Bartolini, M., Pistolozzi, M., Andrisano, V., Egea, J., López, M. G., Iriepa, I., Moraleda, I., Galvez‐Ruano, E., Marco, J. L., & Samadi, A. (2011) · ChemMedChem · doi:10.1002/cmdc.201100239 · Cited by 26 · see citing works

Multifunctional neuroprotective drugs for the treatment of cognitive and movement impairment disorders, including Alzheimer's and Parkinson's diseases

der Schyf, C. J. V., Geldenhuys, W. J., & Youdim, M. B. H. (2006) · Drugs of the Future · doi:10.1358/dof.2006.031.05.985904 · Cited by 24 · see citing works

Bis(9)-(−)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice

Liu, T., Xia, Z., Zhang, W., Xu, J., Ge, X.-X., Li, J., Cui, Y., Qiu, Z., Xu, J., Xie, Q., et al. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.11.009 · Cited by 24 · see citing works

Ketones related to the benzoate 5-HT4 receptor antagonist RS-23597 are high affinity partial agonists

Clark, R. D., Jahangir, A. M., Langston, J., et al. (1994) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)80413-3 · Cited by 20 · see citing works

Synthesis of dual AChE/5-HT4 receptor multi-target directed ligands

Lecoutey, C., Rochais, C., Genest, D., Butt‐Gueulle, S., Ballandonne, C., Corvaisier, S., Dulin, F., Lepailleur, A., Santos, J. S. O., & Dallemagne, P. (2012) · MedChemComm · doi:10.1039/c2md20063e · Cited by 18 · see citing works

Progress in acetylcholinesterase inhibitors for Alzheimer’s disease

Bolognesi, M. L., Minarini, A., Tumiatti, V., & Melchiorre, C. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.6.811 · Cited by 17 · see citing works

A comparison of the pharmacological properties of guinea‐pig and human recombinant 5‐HT4receptors

Vickery, R., Mai, N., Kaufman, E., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707154 · Cited by 14 · see citing works

Multi-target Drugs

Morphy, R., & Ranković, Z. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00027-5 · Cited by 12 · see citing works

Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies

Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331 · see citing works

From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology

Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · see citing works

Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations

Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020) · BioMed Research International · doi:10.1155/2020/5120230 · Cited by 121 · see citing works

In silico repurposing of antipsychotic drugs for Alzheimer’s disease

Kumar, S., Chowdhury, S., & Kumar, S. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0394-8 · Cited by 103 · see citing works

Multi-Target Drug Candidates for Multifactorial Alzheimer’s Disease: AChE and NMDAR as Molecular Targets

Uddin, M. S., Al Mamun, A., Kabir, M. T., Ashraf, G. M., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02116-9 · Cited by 86 · see citing works

Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer’s disease

Hu, J., Pan, T., An, B., Li, Z., Li, X., & Huang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.013 · Cited by 53 · see citing works

Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy

Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51 · see citing works

Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease

Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47 · see citing works

Screening of a Potent Antidementia Acetylcholinesterase Inhibitor-containing Fruits and Optimal Extraction Conditions

이은나, 송정화, & 이종수 (2010) · The Korean Journal of Food And Nutrition · Cited by 6 · see citing works

[Inhibitory properties of cycloguanide phenylsulfone on acetylcholinesterase].

Yuan, B., & Qin, B.-Y. (1990) · PubMed

Inhibitory effect of suberogorgin on acetylcholinesterase.

Peng, W.-D., Xu, S.-B., & Peng, X. (1996) · PubMed · Cited by 2 · see citing works

Expression of acetylcholinesterase in sub regions of brain in different aged rat with chronic unpredictable mild stress

We, R. (2008)

Effect of acetylcholinesterase inhibition on behavior is age-dependent in freely moving Aplysia

Srivatsan, M., & Peretz, B. (1996) · Behavioural Brain Research · doi:10.1016/0166-4328(95)00207-3 · Cited by 12 · see citing works